ganoderic acid T | 112430-70-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: ganoderic acid T
• 英文别名: (E,5S,6S)-5-acetyloxy-6-[(3R,5R,10S,13R,14R,15S,17R)-3,15-diacetyloxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid
• CAS: 112430-70-3；103992-91-2
• 化学式: C₃₆H₅₂O₈
• 分子量: 612.804
• InChiKey: OCLVBEOPEKEKNM-CAXIOAJTSA-N

物化性质

• 沸点：
  683.0±55.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  44
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ganoderic acid T 在 草酰氯 作用下， 以 dichlorocarbene 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Cytotoxic and pro-apoptotic effects of novel ganoderic acid derivatives on human cervical cancer cells in vitro

  摘要：

  Ganoderic acid T, a triterpenic acid produced by Ganoderma lucidum, has demonstrated therapeutic potential for tumor disease. In the current work, ganoderic acid T was modified to produce more effective smallmolecule inhibitors of cancer cell proliferation. Moreover, the anticancer effects of three new ganoderic acid T derivatives, i. e., (22S, 24E)-3a, 15a, 22-triacetoxy-5a-lanosta-7,9(11), 24-trien-26-oic acid ethyl ester (TLTO-Ee), (22S, 24E)-3a, 15a, 22-triacetoxy-5a-lanosta-7,9(11), 24-trien-26-oic acid propyl ester (TLTO-Pe), and (22S, 24E)-3a, 15a, 22-triacetoxy-5a-lanosta-7,9(11), 24-trien-26-oic acid amide (TLTO-A), and one known derivative, (22S, 24E)-3a, 15a, 22-triacetoxy-5a-lanosta-7,9(11), 24-trien-26-oic acid methyl ester (TLTO-Me), on the cervical cell line HeLawere investigated and compared. MTT assay indicated that, among the tested compounds, TLTO-A displayed the highest inhibitory effect on the growth of HeLa cells, whereas it showed less cytotoxicity to the non-tumorous cell line MCF-10A than ganoderic acid T. Flow cytometry analysis revealed that all the compounds caused cell cycle arrest at the G1 phase and induced apoptosis. Furthermore, they decreased the mitochondrialmembrane potential and enhanced the activities of pro-apoptotic factors caspase-3 and caspase-9 in a dose-dependentmanner. Accordingly, the apoptosis induction was presumed to occur through the endogenous pathway. The following order ranks both cytotoxic and pro-apoptotic effects of the compounds against HeLa cells: TLTO-A> ganoderic acid T approximate to TLTO-Me approximate to TLTO-Ee approximate to TLTO-Pe. This study suggests that the carboxyl group of ganoderic acid T is not the main active group and is suitable for its further structural modification. The current work presents valuable information on the design of ganoderic acid T derivatives to develop potential chemotherapy agents. (C) 2012 Elsevier B. V. All rights reserved.

  DOI：

  10.1016/j.ejphar.2012.02.007

文献信息

• Method for extracting oleaginous substances from ganoderma lucidum spores
  申请人：Liu, Xin

  公开号：EP1245235A2

  公开（公告）日：2002-10-02

  The present invention relates to a method for extracting the oleaginous substances from sporoderm-broken Ganoderma spores using SCF-CO2. The method contains the steps of breaking the Ganoderma spores by a mechanical means to obtain the sporoderm-broken spores; and extracting the oleaginous substances from the sporoderm-broken spores using a supercritical fluid - carbon dioxide (SCF-CO2) extraction method. Before breaking the spores by a mechanical means, there may be steps of inducing germination of Ganoderma spores by incubating the spores in a nutritional solution and activating the Ganoderma spores by placing the germination-induced spores in a well ventilated culture box kept at constant temperature and humidity to obtain the sporoderm-broken spores. As for SCF-CO2, the preferred supercritical conditions include 5 M to 60 M Pa of pressure; 32°C to 85°C of temperature; and 5 kg/h to 80 kg/h of flow capacity rate. The total extraction time in SCF-CO2 is between 0.5 hour to 6 hour. The method produces approximately 37% by weight of oleaginous substances from the sporoderm-broken Ganoderma spores. These oleaginous substances are transparent and contain the special fragrance of Ganoderma spores. There is no trace of deposit, solvent residue, or oxidization in the oleaginous substances.

  本发明涉及一种利用 SCF-CO2 从孢子皮破碎的灵芝孢子中提取含油物质的方法。该方法包括以下步骤：用机械方法破碎灵芝孢子，获得孢子破壁孢子；用超临界流体-二氧化碳（SCF- ）萃取法从孢子破壁孢子中提取含油物质。在用机械方法破碎孢子之前，可以有以下步骤：将孢子放在营养液中培养，诱导灵芝孢子发芽；将诱导发芽的孢子放在通风良好、恒温恒湿的培养箱中，激活灵芝孢子，以获得孢子皮破碎的孢子。至于 SCF- ，首选的超临界条件包括：压力 5 兆帕至 60 兆帕；温度 32 摄氏度至 85 摄氏度；流速 5 千克/小时至 80 千克/小时。在 SCF- 中的总萃取时间为 0.5 小时至 6 小时。按重量计，该方法可从孢子皮破损的灵芝孢子中提取约 37% 的含油物质。这些油状物质是透明的，含有灵芝孢子的特殊香味。油状物质中没有沉淀物、溶剂残留物或氧化物的痕迹。
• PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A CANCER ASSOCIATED WITH THE ACTIVATION OF GALECTIN-1
  申请人：Trineo Biotechnology Co. Ltd

  公开号：EP3821949A1

  公开（公告）日：2021-05-19

  Provided herein is a pharmaceutical composition for use in the treatment and/or prophylaxis of a cancer associated with galectin-1. The pharmaceutical composition is administered to a subject and is mainly composed of ganoderic acid S (GAS) and ganoderic acid T (GAT). Another anti-cancer agent can be administered to the subject before, together with, or after the administration of the pharmaceutical composition, so as to synergistically suppress the growth of the cancer.

  本文提供了一种药物组合物，用于治疗和/或预防与galectin-1相关的癌症。该药物组合物主要由甘诺德酸 S（GAS）和甘诺德酸 T（GAT）组成。另一种抗癌剂可在给药组合物之前、同时或之后给受试者使用，以协同抑制癌症的生长。
• METHOD FOR EXTRACTING OLEAGINOUS SUBSTANCES FROM GERMINATION-ACTIVATED GANODERMA LUCIDUM SPORES
  申请人：——

  公开号：US20020131977A1

  公开（公告）日：2002-09-19

  The present invention relates to a method for extracting the oleaginous substances from sporoderm-broken Ganoderma spores using SCF—CO 2 . The method contains the steps of: (1) inducing germination of Ganoderma spores by incubating the spores in a nutritional solution; (2) activating the Ganoderma spores by placing the germination-induced spores in a well ventilated culture box kept at constant temperature and humidity; (3) breaking the Ganoderma spores by a mechanical means to obtain the sporoderm-broken spores; and (4) extracting the oleaginous substances from the sporoderm-broken spores using a supercritical fluid—carbon dioxide (SCF—CO 2 ) extraction method. The preferred supercritical conditions include 5 M to 60 M Pa of pressure; 32° C. to 85° C. of temperature; and 5 kg/h to 80 kg/h of flow capacity rate. The total extraction time in SCF—CO 2 is between 0.5 hour to 6 hour. The method produces approximately 37% by weight of oleaginous substances from the sporoderm-broken Ganoderma spores. These oleaginous substances are transparent and contain the special fragrance of Ganoderma spores. There is no trace of deposit, solvent residue, or oxidization in the oleaginous substances.

  本发明涉及一种利用 SCF-CO 2 .该方法包括以下步骤(1) 将灵芝孢子置于营养液中培养，诱导灵芝孢子萌发； (2) 将诱导萌发的灵芝孢子置于通风良好的恒温恒湿培养箱中，激活灵芝孢子；(3) 用机械方法破碎灵芝孢子，获得孢子体破碎孢子；以及 (4) 用超临界流体-二氧化碳（SCF-CO 2 萃取法。优选的超临界条件包括：压力 5 兆帕至 60 兆帕；温度 32 摄氏度至 85 摄氏度；流速 5 千克/小时至 80 千克/小时。在 SCF-CO 2 中的总萃取时间为 0.5 小时至 6 小时。按重量计，该方法可从孢子皮破损的灵芝孢子中提取约 37% 的含油物质。这些油状物质是透明的，含有灵芝孢子的特殊香味。油状物质中没有沉淀物、溶剂残留物或氧化物的痕迹。
• External preparation for skin containing oleaginous substances extracted from Ganoderma lucidum and method of using the same
  申请人：Chung Chee-Keung

  公开号：US20050180988A1

  公开（公告）日：2005-08-18

  The present invention provides an external preparation for skin which contains, as a major ingredient, oleaginous substances extracted from sporoderm-broken spores from Ganoderma lucidum . The spores are preferably being treated with germination activation. The oleaginous substances are preferred to be extracted by a supercritical fluid-carbon dioxide (SCF-CO 2 ) method. The oleaginous substances prepared by SCF-CO 2 is transparent and odorless. They also demonstrates effects on skin smoothening, wrinkles reduction, aging defiance, inflammation lessening, pigmentation lightening, and irritation alleviation. The external preparation can be a cosmetic or a therapeutic composition.

  本发明提供了一种皮肤外用制剂，其主要成分含有从灵芝孢子-破壁孢子中提取的含油物质。 灵芝 .这些孢子最好经过发芽活化处理。油脂类物质最好通过超临界流体-二氧化碳（SCF-CO 2 )的方法提取。用 SCF-CO 2 制备的油脂类物质透明无味。它们还具有平滑皮肤、减少皱纹、抗衰老、减轻炎症、淡化色斑和减轻刺激的功效。外用制剂可以是化妆品，也可以是治疗组合物。
• Hirotani, Masao; Ino, Chieko; Furuya, Tsutomu, Chemical and pharmaceutical bulletin, 1986, vol. 34, # 5, p. 2282 - 2285
  作者：Hirotani, Masao、Ino, Chieko、Furuya, Tsutomu、Shiro, Motoo

  DOI：——

  日期：——